Viewing Study NCT01292135

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:32 PM
Ignite Modification Date: 2026-01-02 @ 11:01 PM
Study NCT ID: NCT01292135
Status: COMPLETED
Last Update Posted: 2014-07-24
First Post: 2011-02-02
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Sponsor: Pharmacyclics LLC.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None B-cell Chronic Lymphocytic Leukemia View
None Small Lymphocytic Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lymphoma, B-Cell View
None Leukemia, Lymphoid View
None Leukemia, B-Cell View
None Bruton's Tyrosine Kinase View